help button home button Endocrine Society JCEM
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH

This version published online on September 5, 2006
Journal of Clinical Endocrinology & Metabolism, doi:10.1210/jc.2006-0920
A more recent version of this article appeared on November 1, 2006
This Article
Right arrow Author Manuscript (PDF)
Right arrow All Versions of this Article:
91/11/4593    most recent
Author Manuscript (PDF)
Right arrow Submit a related Letter to the Editor
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Copyright Permission
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Pollard, P. J
Right arrow Articles by Maher, E. R
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Pollard, P. J
Right arrow Articles by Maher, E. R

Submitted on May 1, 2006
Accepted on August 29, 2006

Expression of HIF-1{alpha}, HIF-2{alpha} (EPAS1), and their target genes in paraganglioma and phaeochromocytoma with VHL and SDH mutations

Patrick J Pollard, Mona El-Bahrawy, Richard Poulsom, George Elia, Pip Killick, Gavin Kelly, Toby Hunt, Rosemary Jeffery, Pooja Seedhar, Julian Barwell, Farida Latif, Michael J Gleeson, Shirley V Hodgson, Gordon W Stamp, Ian PM Tomlinson, and Eamonn R Maher*

Molecular and Population Genetics Laboratory, Histopathology Service, In Situ Hybridisation Service, and Bioinformatics & Biostatistics Service, London Research Institute, Cancer Research UK, 44, Lincoln's Inn Fields, London WC2A 3PX, UK.;Imperial College Department of Histopathology, Division of Investigative Science, Hammersmith Hospital, DuCane Road, London, W12 0NN, UK, Department of Otolaryngology, Guy's Hospital, London, SE1 9RT, UK.; Department of Clinical Genetics, St Georges Hospital, London SW17 ORE, UK, Cancer Research UK Renal Molecular Oncology Group, Section of Medical and Molecular Genetics, University of Birmingham School of Medicine, Institute of Biomedical Reserach, Birmingham, B15 2TT, UK

* To whom correspondence should be addressed. E-mail: e.r.maher{at}bham.ac.uk.

Context: Activation of the hypoxia inducible transcription factors HIF-1 and HIF-2 and a HIF-independent defect in developmental apoptosis have been implicated in the pathogenesis of phaeochromocytoma(PCC) associated with VHL, SDHB and SDHD mutations. Objective: To compare protein (HIF-1{alpha}, EPAS1, SDHB, JunB, CCND1, CD34, CLU) and gene (VEGF, BNIP3) expression patterns in VHL and SDHB/D associated tumors. Results: Overexpression of HIF-2 was relatively more common in VHL than SDHB/D PCC (12/13 vs. 14/20, P = 0.02), whereas nuclear HIF-1 staining was relatively more frequent in SDHB/D PCC (19/20 vs. 13/16, P = 0.04). In addition CCND1 and VEGF expression (HIF-2 target genes) was significantly higher in VHL -than in SDHB/D PCCs. These findings suggest that VHL inactivation leads to preferential HIF-2 activation and CCND1 expression as described previously in VHL-defective renal cell carcinoma (RCC) cell lines but not in other cell types. These similarities between the downstream consequences of VHL inactivation and HIF dysregulation in RCC and PCC may explain how inactivation of the ubiquitously expressed VHL protein results in susceptibility to specific tumor types. Both VHL and SDHB/D PCC demonstrated reduced CLU and SDHB expression. SDHB PCC are associated with a high risk of malignancy and expression of (proapototic) BNIP3 was significantly lower in SDHB than VHL PCC. Conclusion: Although inactivation of VHL and SDHB/D may disrupt similar HIF-dependent and HIF-independent signaling pathways, their effects on target gene expression are not identical and this may explain the observed clinical differences in PCC and associated tumors seen with germline VHL and SDHB/D mutations.




This article has been cited by other articles:


Home page
J. Med. Genet.Home page
B E Baysal
Clinical and molecular progress in hereditary paraganglioma
J. Med. Genet., November 1, 2008; 45(11): 689 - 694.
[Abstract] [Full Text] [PDF]


Home page
JNCI J Natl Cancer InstHome page
C. Ricketts, E. R. Woodward, P. Killick, M. R. Morris, D. Astuti, F. Latif, and E. R. Maher
Germline SDHB Mutations and Familial Renal Cell Carcinoma
J Natl Cancer Inst, September 3, 2008; 100(17): 1260 - 1262.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH
Endocrinology Endocrine Reviews J. Clin. End. & Metab.
Molecular Endocrinology Recent Prog. Horm. Res. All Endocrine Journals
Copyright © 2006 by The Endocrine Society